These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 36521929)

  • 1. Activated NK cells reprogram MDSCs via NKG2D-NKG2DL and IFN-γ to modulate antitumor T-cell response after cryo-thermal therapy.
    Peng P; Lou Y; Wang S; Wang J; Zhang Z; Du P; Zheng J; Liu P; Xu LX
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36521929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural Killer Cells Reprogram Myeloid-Derived Suppressor Cells to Induce TNF-α Release via NKG2D-Ligand Interaction after Cryo-Thermal Therapy.
    You J; Wang S; Zhu Y; Zhang Z; Wang J; Lou Y; Yao Y; Hao Y; Liu P
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.
    Parihar R; Rivas C; Huynh M; Omer B; Lapteva N; Metelitsa LS; Gottschalk SM; Rooney CM
    Cancer Immunol Res; 2019 Mar; 7(3):363-375. PubMed ID: 30651290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining all-trans retinoid acid treatment targeting myeloid-derived suppressive cells with cryo-thermal therapy enhances antitumor immunity in breast cancer.
    Lou Y; Peng P; Wang S; Wang J; Du P; Zhang Z; Zheng J; Liu P; Xu LX
    Front Immunol; 2022; 13():1016776. PubMed ID: 36389684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Th1-Dominant CD4
    Peng P; Lou Y; Wang J; Wang S; Liu P; Xu LX
    Front Immunol; 2022; 13():944115. PubMed ID: 35874660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mononuclear myeloid-derived "suppressor" cells express RAE-1 and activate natural killer cells.
    Nausch N; Galani IE; Schlecker E; Cerwenka A
    Blood; 2008 Nov; 112(10):4080-9. PubMed ID: 18753637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NKG2D ligand RAE1ε induces generation and enhances the inhibitor function of myeloid-derived suppressor cells in mice.
    Qian L; Liu Y; Wang S; Gong W; Jia X; Liu L; Ye F; Ding J; Xu Y; Fu Y; Tian F
    J Cell Mol Med; 2017 Sep; 21(9):2046-2054. PubMed ID: 28276625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NKG2D-Fc fusion protein promotes antitumor immunity through the depletion of immunosuppressive cells.
    Feng PH; Lam B; Tseng SH; Kung YJ; Farmer E; Cheng MA; Hung CF
    Cancer Immunol Immunother; 2020 Oct; 69(10):2147-2155. PubMed ID: 32468232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells.
    Zhang T; Sentman CL
    Cancer Res; 2011 Mar; 71(6):2066-76. PubMed ID: 21282338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The NKG2D/NKG2DL Axis in the Crosstalk Between Lymphoid and Myeloid Cells in Health and Disease.
    Stojanovic A; Correia MP; Cerwenka A
    Front Immunol; 2018; 9():827. PubMed ID: 29740438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients.
    Srivastava RM; Lee SC; Andrade Filho PA; Lord CA; Jie HB; Davidson HC; López-Albaitero A; Gibson SP; Gooding WE; Ferrone S; Ferris RL
    Clin Cancer Res; 2013 Apr; 19(7):1858-72. PubMed ID: 23444227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.
    Schwinn N; Vokhminova D; Sucker A; Textor S; Striegel S; Moll I; Nausch N; Tuettenberg J; Steinle A; Cerwenka A; Schadendorf D; Paschen A
    Int J Cancer; 2009 Apr; 124(7):1594-604. PubMed ID: 19089914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining Cryo-Thermal Therapy with Anti-IL-6 Treatment Promoted the Maturation of MDSCs to Induce Long-Term Survival in a Mouse Model of Breast Cancer.
    Du P; Zheng J; Wang S; Lou Y; Zhang Z; Wang J; Zhu Y; You J; Zhang A; Liu P
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myeloid-derived suppressor cells confer tumor-suppressive functions on natural killer cells via polyinosinic:polycytidylic acid treatment in mouse tumor models.
    Shime H; Kojima A; Maruyama A; Saito Y; Oshiumi H; Matsumoto M; Seya T
    J Innate Immun; 2014; 6(3):293-305. PubMed ID: 24192491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
    Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural killer group 2D receptor and its ligands in cancer immune escape.
    Duan S; Guo W; Xu Z; He Y; Liang C; Mo Y; Wang Y; Xiong F; Guo C; Li Y; Li X; Li G; Zeng Z; Xiong W; Wang F
    Mol Cancer; 2019 Feb; 18(1):29. PubMed ID: 30813924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myeloid-derived suppressor cells inhibit natural killer cells in myelodysplastic syndromes through the TIGIT/CD155 pathway.
    Yue J; Li J; Ma J; Zhai Y; Shen L; Zhang W; Li L; Fu R
    Hematology; 2023 Dec; 28(1):2166333. PubMed ID: 36651499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia.
    Märklin M; Hagelstein I; Koerner SP; Rothfelder K; Pfluegler MS; Schumacher A; Grosse-Hovest L; Jung G; Salih HR
    J Immunother Cancer; 2019 May; 7(1):143. PubMed ID: 31142382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting NKG2D/NKG2DL axis in multiple myeloma therapy.
    Liu Z; Wang H; Liu H; Ding K; Shen H; Zhao X; Fu R
    Cytokine Growth Factor Rev; 2024 Apr; 76():1-11. PubMed ID: 38378397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumour-experienced T cells promote NK cell activity through trogocytosis of NKG2D and NKp46 ligands.
    Domaica CI; Fuertes MB; Rossi LE; Girart MV; Avila DE; Rabinovich GA; Zwirner NW
    EMBO Rep; 2009 Aug; 10(8):908-15. PubMed ID: 19498463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.